{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:31:36Z","timestamp":1787311896937,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-96764-3","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T09:06:47Z","timestamp":1744016807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development and validation of an LC\u2013MS\/MS method for quantitative determination of LXT-101 sustained-release suspension, a novel drug in treating prostate cancer, in beagle plasma"],"prefix":"10.1038","volume":"15","author":[{"given":"Jinglai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"1","key":"96764_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 68(1), 7\u201330 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"96764_CR2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"96764_CR3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.eururo.2016.10.008","volume":"71","author":"GW Dy","year":"2017","unstructured":"Dy, G. W., Gore, J. L., Forouzanfar, M. H., Naghavi, M. & Fitzmaurice, C. Global burden of urologic cancers, 1990\u20132013. Eur. Urol. 71(3), 437\u2013446 (2017).","journal-title":"Eur. Urol."},{"issue":"5","key":"96764_CR4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","volume":"70","author":"MC Wong","year":"2016","unstructured":"Wong, M. C. et al. Global incidence and mortality for prostate cancer: Analysis of temporal patterns and trends in 36 countries. Eur. Urol. 70(5), 862\u2013874 (2016).","journal-title":"Eur. Urol."},{"issue":"1","key":"96764_CR5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello, R. J. et al. Prostate cancer. Nat. Rev. Dis. Primers. 7(1), 9 (2021).","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"17\u201318","key":"96764_CR6","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1101\/gad.315739.118","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang, G., Zhao, D., Spring, D. J. & DePinho, R. A. Genetics and biology of prostate cancer. Genes Dev. 32(17\u201318), 1105\u20131140 (2018).","journal-title":"Genes Dev."},{"issue":"5 Suppl","key":"96764_CR7","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/cncr.1990.66.s5.1035","volume":"66","author":"ED Crawford","year":"1990","unstructured":"Crawford, E. D. Hormonal therapy of prostatic carcinoma: Defining the challeng. Cancer 66(5 Suppl), 1035\u20131038 (1990).","journal-title":"Cancer"},{"issue":"1","key":"96764_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0022-5347(01)66524-8","volume":"155","author":"HA Guess","year":"1996","unstructured":"Guess, H. A., GormLey, G. J., Stoner, E. & Oesterling, J. E. The effect of finasteridem on prostate specifica antigen: Review of available data. J. Urol. 155(1), 3\u20139 (1996).","journal-title":"J. Urol."},{"issue":"8","key":"96764_CR9","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1200\/JCO.1993.11.8.1566","volume":"11","author":"HI Scher","year":"1993","unstructured":"Scher, H. I. & Kelly, W. K. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. 11(8), 1566\u20131572 (1993).","journal-title":"J. Clin. Oncol."},{"issue":"1\u20133","key":"96764_CR10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.regpep.2006.05.004","volume":"136","author":"X Chi","year":"2006","unstructured":"Chi, X., Zhou, W., Cheng, J., Zhang, Y. & Liu, K. In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats. Regul. Pept. 136(1\u20133), 122\u2013129 (2006).","journal-title":"Regul. Pept."},{"issue":"9","key":"96764_CR11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1248\/cpb.54.1259","volume":"54","author":"L Du","year":"2006","unstructured":"Du, L. et al. Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist. Chem. Pharm. Bull. (Tokyo). 54(9), 1259\u20131265 (2006).","journal-title":"Chem. Pharm. Bull. (Tokyo)."},{"issue":"7","key":"96764_CR12","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.2042-7158.2011.01295.x","volume":"63","author":"T Wang","year":"2011","unstructured":"Wang, T., Gao, L. & Quan, D. Multivesicular liposome (MVL) sustained delivery of a novel synthetic cationic GnRH antagonist for prostate cancer treatment. J. Pharm. Pharmacol. 63(7), 904\u2013910 (2011).","journal-title":"J. Pharm. Pharmacol."},{"issue":"1\u20132","key":"96764_CR13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijpharm.2013.04.047","volume":"450","author":"G Zhang","year":"2013","unstructured":"Zhang, G., Wang, T., Gao, L. & Quan, D. Oral delivery of oil-based formulation for a novel synthetic cationic peptide of GnRH (gonadotropin-releasing hormone) antagonist for prostate cancer treatment. Int. J. Pharm. 450(1\u20132), 138\u2013144 (2013).","journal-title":"Int. J. Pharm."},{"issue":"8","key":"96764_CR14","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/jphp.12233","volume":"66","author":"G Zhang","year":"2014","unstructured":"Zhang, G., Li, J., Gao, L., Wang, T. & Quan, D. Morphology of nanostructures and their long-acting properties in vivo for a novel synthetic peptide of gonadotropin-releasing hormone antagonist. J. Pharm. Pharmacol. 66(8), 1077\u20131081 (2014).","journal-title":"J. Pharm. Pharmacol."},{"key":"96764_CR15","unstructured":"US-FDA. Bioanalytical Method Validation Guidance for Industry, US-FDA, Silver Spring, MD, USA, 2018. https:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-drugsgen\/documents\/document\/ucm070107.pdf."},{"key":"96764_CR16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jpba.2018.12.036","volume":"166","author":"RA Xu","year":"2019","unstructured":"Xu, R. A. et al. UPLC-MS\/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. J. Pharm. Biomed. Anal. 166, 6\u201312 (2019).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"96764_CR17","volume":"11","author":"C Tang","year":"2020","unstructured":"Tang, C. et al. In vivo Pharmacokinetic drug-drug interaction studies between fedratinib and antifungal agents based on a newly developed and validated UPLC\/MS-MS method. Front. Pharmacol. 11, 626897 (2020).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"96764_CR18","first-page":"121","volume":"16","author":"G Feng","year":"2024","unstructured":"Feng, G. et al. Effect of Rhei Radix et Rhizoma and Eupolyphaga Steleophaga on liver protection mechanism based on pharmacokinetics and metabonomics. Chin. Herb Med. 16(1), 121\u2013131 (2024).","journal-title":"Chin. Herb Med."},{"issue":"1","key":"96764_CR19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/13880209.2022.2048862","volume":"60","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Liu, Y. N., Xie, S., Xu, X. & Xu, R. A. Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC-MS\/MS assay. Pharm. Biol. 60(1), 621\u2013626 (2022).","journal-title":"Pharm. Biol."},{"issue":"3","key":"96764_CR20","first-page":"457","volume":"16","author":"X Li","year":"2024","unstructured":"Li, X. et al. Comparative pharmacokinetics of six components in normal and rheumatoid arthritis rats after intragastrical administration of Qianghuo Shengshi Decoction granules by LC-MS\/MS. Chin. Herb. Med. 16(3), 457\u2013465 (2024).","journal-title":"Chin. Herb. Med."},{"issue":"3","key":"96764_CR21","first-page":"466","volume":"16","author":"P Wei","year":"2024","unstructured":"Wei, P. et al. Identification and characterization of chemical constituents in Mahuang Guizhi Decoction and their metabolites in rat plasma and brain by UPLC-Q-TOF\/MS. Chin. Herb. Med. 16(3), 466\u2013480 (2024).","journal-title":"Chin. Herb. Med."},{"key":"96764_CR22","doi-asserted-by":"crossref","first-page":"1148332","DOI":"10.3389\/fphar.2023.1148332","volume":"14","author":"S Xiong","year":"2023","unstructured":"Xiong, S. et al. Comparative pharmacokinetics of four major compounds after oral administration of Mori Cortex total flavonoid extract in normal and diabetic rats. Front. Pharmacol. 14, 1148332 (2023).","journal-title":"Front. Pharmacol."},{"issue":"3","key":"96764_CR23","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5803","volume":"38","author":"W Cheng","year":"2024","unstructured":"Cheng, W. et al. Simultaneous determination of five compounds of fried Radix Paeoniae Alba extract in beagle dogs plasma by Ultra Performance Liquid Chromatography Tandem Mass Spectrometry and its application in a pharmacokinetic study. Biomed. Chromatogr. 38(3), e5803 (2024).","journal-title":"Biomed. Chromatogr."},{"issue":"12","key":"96764_CR24","volume":"36","author":"X Yu","year":"2022","unstructured":"Yu, X. et al. Simultaneous determination and pharmacokinetic study of six components in beagle dog plasma by UPLC-MS\/MS after oral administration of Astragalus Membranaceus aqueous extract. Biomed. Chromatogr. 36(12), e5488 (2022).","journal-title":"Biomed. Chromatogr."},{"issue":"3","key":"96764_CR25","first-page":"28","volume":"8","author":"A Barsouk","year":"2020","unstructured":"Barsouk, A. et al. Epidemiology, staging and management of prostate cancer. Med. Sci. (Basel). 8(3), 28\u201341 (2020).","journal-title":"Med. Sci. (Basel)."},{"issue":"1","key":"96764_CR26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7\u201330 (2020).","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"96764_CR27","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/00005392-200204000-00021","volume":"167","author":"J Trachtenberg","year":"2002","unstructured":"Trachtenberg, J. et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J. Urol. 167(4), 1670\u20131674 (2002).","journal-title":"J. Urol."},{"issue":"11","key":"96764_CR28","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz, L. et al. The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 102(11), 1531\u20131538 (2008).","journal-title":"BJU Int."},{"issue":"6","key":"96764_CR29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2174\/1566523215666150929110424","volume":"15","author":"C Gopinath","year":"2015","unstructured":"Gopinath, C., Nathar, T. J., Ghosh, A., Hickstein, D. D. & Nelson, E. J. R. Contemporary animal models for human gene therapy applications. Curr. Gene Ther. 15(6), 531\u2013540 (2015).","journal-title":"Curr. Gene Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96764-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96764-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96764-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T09:08:13Z","timestamp":1744016893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96764-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96764"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96764-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments were demonstrated to be ethically acceptable and were carried out according to the Guidelines of the Experimental Animal Care and Use of Laboratory Animals of the Beijing Institute of Pharmacology and Toxicology. All the animal protocols for experiments were approved by the Institutional Animal Care and Use Committee of the Beijing Institute of Pharmacology and Toxicology (nos 11400700031606). This study was reported in accordance with ARRIVE guidelines (\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"11868"}}